Guggenheim Has Lowered Expectations for Absci (NASDAQ:ABSI) Stock Price

Absci (NASDAQ:ABSI – Get Free Report) had its price target reduced by investment analysts at Guggenheim from $15.00 to $14.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s target price suggests a potential upside of 81.14% from the company’s previous close.

ABSI has been the subject of a number of other research reports. Lifesci Capital initiated coverage on shares of Absci in a research report on Wednesday, September 9th. They set an “outperform” rating for the company. KeyCorp lifted their target price on shares of Absci from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, October 16th. BTIG Research reissued a “buy” rating and issued a $16.00 target price on shares of Absci in a research report on Thursday. Wall Street Zen raised Absci from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Jefferies Financial Group started coverage on Absci in a research note on Thursday, October 29th. They set a “buy” rating and a $14.00 price target on the stock. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.90.

Check Out Our Latest Research Report on Absci

Absci Price Performance

Shares of ABSI stock opened at $7.73 on Monday. The firm has a market cap of $1.33 billion, a PE ratio of -10.18 and a beta of 2.22. The company has a 50-day moving average of $9.65 and a two-hundred day moving average of $6.81. Absci has a 1-year low of $2.24 and a 1-year high of $12.54.

Absci (NASDAQ:ABSI – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.19). The business had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.66 million. Absci had a negative net margin of 8,451.31% and a negative return on equity of 61.60%. Sell-side analysts anticipate that Absci will post -0.76 EPS for the current fiscal year.

Institutional Trading of Absci

A number of institutional investors and hedge funds have recently bought and sold shares of ABSI. BlackRock Inc. purchased a new position in shares of Absci in the second quarter valued at approximately $141,112,000. Marshall Wace LLP grew its holdings in shares of Absci by 287.3% in the third quarter. Marshall Wace LLP now owns 1,945,901 shares of the company’s stock valued at $20,957,000 after purchasing an additional 1,443,494 shares in the last quarter. Siren L.L.C. acquired a new position in shares of Absci in the first quarter valued at approximately $5,400,000. Parkman Healthcare Partners LLC purchased a new stake in Absci during the 2nd quarter worth approximately $10,366,000. Finally, Bank of America Corp DE purchased a new stake in Absci during the 2nd quarter worth approximately $6,560,000. 52.05% of the stock is currently owned by hedge funds and other institutional investors.

Absci Company Profile

(Get Free Report)

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.

Featured Articles

Analyst Recommendations for Absci (NASDAQ:ABSI)

Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.